ArticleJournal of inflammation research2026
Nonlinear Relationship of Leukocyte-to-Albumin Ratio with Disease Activity in Rheumatoid Arthritis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The assessment of disease activity in rheumatoid arthritis (RA) is crucial for clinical management. In recent years, composite inflammatory markers, such as the leukocyte-to-albumin ratio (LAR), have demonstrated prognostic value in various diseases; however, its relevance in RA remains unclear. This study aims to investigate the association between LAR and disease activity in RA, as measured by the DAS28-ESR and DAS28-CRP scores. Methods: This retrospective study enrolled 1070 patients with RA, who were categorized into three groups based on LAR tertiles: T1 (0.06-0.14), T2 (0.14-0.19), and T3 (0.19-0.88). Demographic characteristics, laboratory parameters (including inflammatory markers, complete blood count, and biochemical indicators), and disease activity scores were collected. Univariate analysis, multivariate linear regression, and piecewise linear regression models were employed to evaluate the association between LAR and DAS28 scores, with adjustments for confounding factors such as sex, age, and medication use. Results: Patients in the high-LAR group (T3) exhibited significantly elevated levels of inflammatory markers (ESR, CRP, and fibrinogen; all P < 0.001) and lower albumin levels (P < 0.001). Univariate analysis revealed a significant positive correlation between LAR and both DAS28-ESR (β = 3.949, P < 0.001) and DAS28-CRP (β = 4.804, P < 0.001). After multivariate adjustment, LAR remained independently associated with DAS28-ESR (β = 1.846, P < 0.001) and DAS28-CRP (β = 2.450, P < 0.001). Piecewise regression analysis identified an inflection point in the LAR-DAS28 relationship at LAR = 0.20. Below this threshold, the association was stronger (DAS28-ESR β = 6.33, P < 0.001), whereas above 0.20, the association was attenuated yet remained significant (β = 2.03, P < 0.001). Conclusion: LAR is an independent factor associated with disease activity in RA, with a particularly pronounced correlation observed in the lower LAR range. These findings suggest that LAR may serve as a simple and cost-effective auxiliary indicator for clinical assessment of inflammatory status and disease activity in RA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.